Article Information
History
- June 30, 2022.
Article Versions
- You are currently viewing Version 1 of this article (June 30, 2022 - 17:07).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Dr Catherine Hyams, PhD†,1,
- Dr Robert Challen, MA MBBS2,†,
- Dr Robin Marlow, PhD1,
- Dr Jennifer Nguyen, ScD, MPH3,
- Dr Elizabeth Begier, MD, MPH4,
- Dr Jo Southern, PhD5,
- Ms Jade King, MSc6,
- Ms Anna Morley, MSc7,
- Ms Jane Kinney, BSc8,
- Ms Madeleine Clout, BSc8,
- Dr Jennifer Oliver, PhD8,
- Dr Gillian Ellsbury, MD5,
- Prof Nick Maskell, MD7,
- Dr Luis Jodar, PhD3,
- Dr Bradford Gessner, PhD3,
- Dr John McLaughlin, PhD3,
- Dr Leon Danon, PhD2,
- Professor Adam Finn, PhD FRCP9,*,
- The Avon CAP Research Group
- 1Population Health Sciences, University of Bristol, Bristol, UK
- 2Engineering Mathematics, University of Bristol, UK
- 3Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA
- 4Global Medical Development Scientific and Clinical Affairs, Pfizer Vaccines, Ireland
- 5Vaccines Medical Affairs, Pfizer Ltd, Tadworth, UK, KT20 7NS
- 6Vaccine and Testing Team, Clinical Research Facility, UHBW NHS Trust, Bristol, UK
- 7Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, UK
- 8Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
- 9Bristol Vaccine Centre, Cellular and Molecular Medicine and Population Health Sciences, University of Bristol, Bristol, UK
- ↵*Corresponding Author:
Professor Adam Finn, PhD, Bristol Vaccine Centre, University of Bristol, Level 6, UHB Education and Research Centre, Upper Maudlin Street, Bristol BS2 8AE, United Kingdom, +44(0)117 342 0160, adam.finn{at}bristol.ac.uk
↵† These authors contributed equally, and should be considered co-first authors